Business Context and Reporting Period
Company: Actinium Pharmaceuticals, Inc. (ATNM)
Filing Type: Form 10-Q (Unaudited)
Period Ended: September 30, 2025
Business Overview: Actinium is a clinical-stage biopharmaceutical company developing targeted radiotherapies for advanced cancers. The company focuses on solid tumors (via ATNM-400), hematology (via Actimab-A), and conditioning for cellular therapies (via Iomab-ACT and Iomab-B). As of the filing date, the company had 25 full-time employees and approximately 250 issued and pending patents worldwide.
Key Financial Metrics
| Financial Metric (in thousands) | Q3 2025 | Q3 2024 | 9 Months 2025 | 9 Months 2024 |
|---|---|---|---|---|
| Total Revenue | $90 | $0 | $90 | $0 |
| Net Loss | $(5,131) | $(11,568) | $(27,947) | $(31,591) |
| Net Loss Per Share (Basic & Diluted) | $(0.16) | $(0.37) | $(0.90) | $(1.06) |
| Operating Expenses | $5,782 | $12,601 | $29,923 | $34,616 |
| Cash and Cash Equivalents (End of Period) | $53,391 | $72,904 | $53,391 | $72,904 |
| Net Cash Used in Operating Activities (9 Months) | $(19,291) | $(27,321) | $(19,291) | $(27,321) |
| Accumulated Deficit | $(403,773) | $(375,826) | $(403,773) | $(375,826) |
Note: Revenue consists entirely of grant revenue ($0.1 million) from a government-sponsored entity. There was no commercial product revenue.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by 54% in Q3 2025 compared to Q3 2024 ($5.8M vs. $12.6M). This was driven by a 56% reduction in R&D expenses and a 46% reduction in G&A expenses, primarily due to a workforce optimization in Q2 2025 (approx. 14% headcount reduction) and lower CRO costs.
- Stock-Based Compensation Volatility: While Q3 2025 stock-based compensation was lower than the prior year due to option cancellations, the nine-month 2025 period saw a significant increase in total stock-based compensation ($9.2M vs. $4.1M in 2024). This increase was caused by the acceleration of expense recognition upon the cancellation of 4.9 million stock options in March 2025.
- Liquidity Position: Cash and cash equivalents decreased by approximately $19.5 million during the nine months ended September 30, 2025, compared to a slight increase in the prior year period. The company did not sell any shares of common stock in the first nine months of 2025, whereas it raised approximately $29.3 million net in the same period in 2024.
- Deferred Revenue: Long-term license revenue deferred remained constant at $35.0 million, representing an upfront payment from Immedica Pharma AB for Iomab-B rights in the EUMENA region, pending regulatory approval.
Guidance, Outlook, Risks, and Unusual Items
Management Commentary and Outlook
- Pipeline Prioritization: Management is prioritizing ATNM-400 (pan-tumor alpha-targeted radiotherapy) for solid tumors (prostate, NSCLC, breast) and Actimab-A for hematology. Preclinical data presented in late 2025 showed potent efficacy for ATNM-400 compared to standard therapies.
- Strategic Partnering: The company is actively seeking a strategic partner for Iomab-B in the U.S. to fund and execute additional FDA-required clinical trials (Phase 2/3) following the FDA's determination that the prior SIERRA trial data was insufficient for a Biologics License Application (BLA).
- Liquidity Runway: Management expects existing resources to fund planned operations for more than 12 months following the filing date.
Risks and Contingencies
- Legal Proceedings: A putative securities class action lawsuit (Kohil v. Actinium Pharmaceuticals, Inc.) was filed in March 2025 alleging misrepresentations regarding the Iomab-B Phase 3 Sierra Trial. An amended complaint was filed in August 2025, and the company moved to dismiss in October 2025. Derivative shareholder complaints were consolidated and stayed pending the resolution of the class action.
- Regulatory Hurdles: The FDA requires an additional head-to-head Phase 3 trial and a dose optimization study for Iomab-B before a BLA can be filed. The company is also facing potential delays in NCI-sponsored trials due to the U.S. federal government shutdown (October 1 – November 12, 2025).
- Third-Party Disputes: In August 2025, Novartis Pharmaceuticals sent a letter objecting to Actinium's statements comparing ATNM-400 to Novartis's Pluvicto. Actinium maintains its statements were accurate based on preclinical data and has not responded but reserves all rights.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $19.3M cash burn over nine months against the $53.4M cash balance to confirm the >12 month runway assertion.
- Stock Option Cancellation Impact: Review the $8.8M non-cash charge recorded in Q1 2025 due to option cancellations to understand the distortion in GAAP expenses for the nine-month period.
- Iomab-B Regulatory Path: Assess the feasibility and cost of the additional FDA-required Phase 2/3 trials for Iomab-B and the status of the search for a U.S. strategic partner.
- Legal Exposure: Monitor the status of the Kohil securities class action and the derivative lawsuits, as an adverse outcome could result in significant damages.
- Government Shutdown Impact: Evaluate the extent of delays to the NCI CRADA trials for Actimab-A resulting from the October-November 2025 government shutdown.